Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: Daptomycin as a motivating exam

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3162-3167

  Pai, Manjunath P ^a   Russo, Alessandro ^b   Novelli, Andrea ^c   Venditti, Mario ^b   Falcone, Marco ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG INFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; MULTIPLE DRUG DOSE; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE; ALGORITHM; COMPUTER SIMULATION; CRITICAL ILLNESS; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MORBID OBESITY; POPULATION; REPRODUCIBILITY; STAPHYLOCOCCUS AUREUS;

ADULT; ALGORITHMS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; COMPUTER SIMULATION; CRITICAL ILLNESS; DAPTOMYCIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; OBESITY, MORBID; POPULATION; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCUS AUREUS;

EID: 84901277998     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02355-14     Document Type: Article

References (22)

1. Martinez MN, Papich MG, Drusano GL. 2012. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharma-cokinetic/pharmacodynamic target. Antimicrob. Agents Chemother. 56: 2795-2805. http://dx.doi.org/10.1128/AAC.05360-11.
2. Varghese JM, Roberts JA, Lipman J. 2011. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit. Care Clin. 27:19-34. http://dx.doi.org/10.1016/j.ccc.2010.09.006.
3. Udy AA, Roberts JA, Lipman J. 2013. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med. 39: 2070-2082. http://dx.doi.org/10.1007/s00134-013-3088-4.
4. Pai MP, Rodvold KA. 22 November 2013. Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity. Diagn. Microbiol. Infect. Dis. http://dx.doi.org/10.1016/j.diagmicrobio.2013.10.011.
5. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr., Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98. http://dx.doi.org/10.2146/ajhp080434.
6. Eisenstein BI, Oleson FB, Jr., Baltz RH. 2010. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin. Infect. Dis. 50(Suppl 1):S10-S15. http://dx.doi.org/10.1086/647938.
7. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak JM, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292. http://dx.doi.org/10.1093/cid/cir034.
8. Falcone M, Russo A, Venditti M, Novelli A, Pai MP. 2013. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 57: 1568-1576. http://dx.doi.org/10.1093/cid/cit582.
9. Di Paolo A, Tascini C, Polillo M, Gemignani G, Nielsen EI, Bocci G, Karlsson MO, Menichetti F, Danesi R. 2013. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Int. J. Antimicrob. Agents 42:250-255. http://dx.doi.org/10.1016/j.ijantimicag.2013.06. 006.
10. Pea F, Crapis M, Cojutti P, Bassetti M. 25 July 2013. Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Infection http://dx.doi.org/10.1007/ s15010-013-0511-2.
11. Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, d'Ettorre G, Fallani S, Novelli A, Venditti M. 2013. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J. Infect. Chemother. 19:732-739. http://dx.doi.org/10.1007/s10156-013-0559-z.
12. Pea F, Cojutti P, Sbrojavacca R, Cadeo B, Cristini F, Bulfoni A, Furlanut M. 2011. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann. Pharmacother. 45: e37. http://dx.doi.org/10.1345/ aph.1P745.
13. Jelliffe RW, Schumitzky A. 1990. Modeling, adaptive control, and optimal drug therapy. Med. Prog. Technol. 16:95-110.
14. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
15. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. 2010. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis. 50:1568-1574. http://dx.doi.org/10.1086/652767.
16. Begg EJ, Barclay ML, Duffull SB. 1995. A suggested approach to oncedaily aminoglycoside dosing. Br. J. Clin. Pharmacol. 39:605-609. http://dx.doi.org/10. 1111/j.1365-2125.1995.tb05719.x.
17. Sawchuk RJ, Zaske DE. 1976. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J. Pharmacokinet. Biopharm. 4:183-195.
18. Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC. 2007. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob. Agents Chemother. 51: 2741-2747. http://dx.doi.org/10.1128/AAC.00059-07.
19. EUCAST. 13 September 2005. Daptomycin: rationale for the EUCAST clinical breakpoints, version 1.0. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST- files/Rationale-documents/Daptomycinrationale1.0.pdf. Accessed 10 October 2013.
20. Tsai IL, Sun HY, Chen GY, Lin SW, Kuo CH. 2013. Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry. Talanta 116:593-603. http://dx.doi.org/10.1016/j.talanta. 2013.07.043.
21. Baietto L, D'Avolio A, Pace S, Simiele M, Marra C, Ariaudo A, Di Perri G, Rosa FG. 2013. Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. J. Pharm. Biomed. Anal. 88C:66-70. http://dx.doi.org/10.1016/j.jpba.2013.08.022.
22. Meesters RJ, Hooff GP. 2013. State-of-the-Art dried blood spot analysis: an overview of recent advances and future trends. Bioanalysis 5:2187-2208. http://dx.doi.org/10.4155/bio.13.175.